检索范围:
排序: 展示方式:
Complex interplay between tumor microenvironment and cancer therapy
null
《医学前沿(英文)》 2018年 第12卷 第4期 页码 426-439 doi: 10.1007/s11684-018-0663-7
Tumor microenvironment (TME) is comprised of cellular and non-cellular components that exist within and around the tumor mass. The TME is highly dynamic and its importance in different stages of cancer progression has been well recognized. A growing body of evidence suggests that TME also plays pivotal roles in cancer treatment responses. TME is significantly remodeled upon cancer therapies, and such change either enhances the responses or induces drug resistance. Given the importance of TME in tumor progression and therapy resistance, strategies that remodel TME to improve therapeutic responses are under developing. In this review, we provide an overview of the essential components in TME and the remodeling of TME in response to anti-cancer treatments. We also summarize the strategies that aim to enhance therapeutic efficacy by modulating TME.
关键词: tumor microenvironment therapy response treatment resistance
Heterogeneity of the tumor immune microenvironment and clinical interventions
《医学前沿(英文)》 2023年 第17卷 第4期 页码 617-648 doi: 10.1007/s11684-023-1015-9
Kai Shi, Matthew Haynes, Leaf Huang
《化学科学与工程前沿(英文)》 2017年 第11卷 第4期 页码 676-684 doi: 10.1007/s11705-017-1640-4
关键词: vaccine nanoparticle tumor immunotherapy microenvironment
《医学前沿(英文)》 2023年 第17卷 第4期 页码 699-713 doi: 10.1007/s11684-022-0972-8
关键词: anti-CD19 chimeric antigen receptor T immunotherapy diffuse large B cell lymphoma tumor microenvironment tumor-associated macrophage metabolism
Hui QIU, Hui ZHANG, Zuohua FENG
《医学前沿(英文)》 2009年 第3卷 第1期 页码 20-25 doi: 10.1007/s11684-009-0006-9
关键词: 4-1BB ligand tumor immunotherapy tumor microenvironment
Immunometabolism: a new dimension in immunotherapy resistance
《医学前沿(英文)》 2023年 第17卷 第4期 页码 585-616 doi: 10.1007/s11684-023-1012-z
关键词: immune cell immunometabolism metabolic reprogramming immunotherapy resistance tumor microenvironment immune checkpoint inhibitor
Translational medicine in hepatocellular carcinoma
null
《医学前沿(英文)》 2012年 第6卷 第2期 页码 122-133 doi: 10.1007/s11684-012-0193-7
Hepatocellular carcinoma (HCC) is a highly complex disease that is generally resistant to commonly used chemotherapy and radiotherapy. Consequently, there is an urgent need for the development of new treatment strategies for this devastating disease. In the past decade, tremendous progress has been achieved in the molecular stratification of HCCs for diagnosis, prognosis, and therapeutic decision-making. To date, the molecular classification of HCCs has been carried out through transcriptomic, genetic and epigenetic profiling of tumors. Such research has led to identification of several potential molecular targets in HCC, and subsequently, development of novel systemic agents for the treatment of HCC has begun in earnest. In this article, we review the current knowledge of the molecular pathogenesis of HCC and outline potential areas for application of this knowledge in a clinical setting. As a typical virus and inflammation-associated cancer, both host immune response and tumor microenvironment have crucial roles in HCC pathogenesis. In addition, we examine the potential of immunotherapy and strategies targeting various components of the tumor microenvironment, as well as novel molecular and cellular targets in HCC such as cancer stem cells.
关键词: hepatocellular carcinoma molecular classification molecular targeted therapies tumor microenvironment immunotherapy
Zhaoshi Bao, Yongzhi Wang, Qiangwei Wang, Shengyu Fang, Xia Shan, Jiguang Wang, Tao Jiang
《医学前沿(英文)》 2021年 第15卷 第4期 页码 551-561 doi: 10.1007/s11684-020-0760-2
关键词: glioma evolution mechanism strategies tumor heterogeneity secondary glioma
Immunological effects of nano-enabled hyperthermia for solid tumors: opportunity and challenge
《化学科学与工程前沿(英文)》 2022年 第16卷 第3期 页码 333-344 doi: 10.1007/s11705-021-2059-5
关键词: nano-enabled hyperthermia immunogenic cell death heterogeneous immunological landscape tumor microenvironment
纳米技术——一种针对促肿瘤中性粒细胞的肺癌治疗新策略 Review
张健, 蒋莎莎, 李仕林, 江继鹏, 梅婕, 陈延东, 马永富, 刘阳, 刘颖
《工程(英文)》 2023年 第27卷 第8期 页码 106-126 doi: 10.1016/j.eng.2022.11.006
原发性肺癌和转移性肺癌都是肺部恶性肿瘤,两者都威胁着患者的生命,但各自的发病机制不同。肿瘤的发生和发展涉及肿瘤细胞与宿主微环境之间的交流,中性粒细胞是肿瘤微环境(TME)中最丰富的免疫细胞,它们参与炎症环境的形成,并通过其抗肿瘤和促肿瘤能力影响患者的生存。中性粒细胞可根据不同的标准分为不同的类别,常见的类别包括 N1 抗肿瘤中性粒细胞和 N2 免疫抑制中性粒细胞。中性粒细胞的抗肿瘤作用是通过活性氧、肿瘤坏死因子相关的细胞凋亡诱导配体、高级糖化终产物受体-胰蛋白酶 G 等因素共同作用以及调节其他免疫细胞的活动共同介导的。中性粒细胞作为肿瘤促进因子,也可通过影响包括癌症发生、血管生成、癌细胞增殖和侵袭能力等过程,促进肺癌的发展和转移,并在其他癌症的肺转移中发挥类似作用。纳米技术的快速发展为针对中性粒细胞的癌症治疗提供了新策略。
《医学前沿(英文)》 doi: 10.1007/s11684-023-1017-7
关键词: single-cell RNA-seq glioma radial glia primitive oligodendrocyte precursor cell immune escape
Proteins moonlighting in tumor metabolism and epigenetics
Lei Lv, Qunying Lei
《医学前沿(英文)》 2021年 第15卷 第3期 页码 383-403 doi: 10.1007/s11684-020-0818-1
Progress in tumor vascular normalization for anticancer therapy: challenges and perspectives
null
《医学前沿(英文)》 2012年 第6卷 第1期 页码 67-78 doi: 10.1007/s11684-012-0176-8
Antitumor angiogenic therapy has been shown promising in the treatment of several advanced cancers since the approval of the first antiangiogenic drug Avastin in 2004. Although the current antiangiogenic drugs reduce the density of tumor blood vessels and result in tumor shrinkage at the early stage of treatment, recent studies have shown that antiangiogenic therapy has transient and insufficient efficacy, resulting in tumor recurrence in patients after several months of treatment. Blockage of blood and oxygen supplies creates a hypoxic and acidic microenvironment in the tumor tissues, which fosters tumor cells to become more aggressive and metastatic. In 2001, Jain proposed tumor vascular normalization as an alternative approach to treating cancers based on the pioneering work on tumor blood vessels by several other researchers. At present, normalizing the disorganized tumor vasculature, rather than disrupting or blocking them, has emerged as a new option for anticancer therapy. Preclinical and clinical data have shown that tumor vascular normalization using monoclonal antibodies, proteins, peptides, small molecules, and pericytes resulted in decreased tumor size and reduced metastasis. However, current tumor vascular normalizing drugs display moderate anticancer efficacy. Accumulated data have shown that a variety of vasculogenic/angiogenic tumor cells and genes play important roles in tumor neovascularization, growth, and metastasis. Therefore, multiple-targeting of vasculogenic tumor cells and genes may improve the efficacy of tumor vascular normalization. To this end, the combination of antiangiogenic drugs with tumor vascular normalizing therapeutics, as well as the integration of Western medicine with traditional Chinese medicine, may provide a good opportunity for discovering novel tumor vascular normalizing drugs for an effective anticancer therapy.
关键词: angiogenesis vasculogenesis neovascularization tumor vasculature normalization traditional Chinese medicine
Natural killer cell lines in tumor immunotherapy
null
《医学前沿(英文)》 2012年 第6卷 第1期 页码 56-66 doi: 10.1007/s11684-012-0177-7
Natural killer (NK) cells are considered to be critical players in anticancer immunity. However, cancers are able to develop mechanisms to escape NK cell attack or to induce defective NK cells. Current NK cell-based cancer immunotherapy is aimed at overcoming NK cell paralysis through several potential approaches, including activating autologous NK cells, expanding allogeneic NK cells, usage of stable allogeneic NK cell lines and genetically modifying fresh NK cells or NK cell lines. The stable allogeneic NK cell line approach is more practical for quality-control and large-scale production. Additionally, genetically modifying NK cell lines by increasing their expression of cytokines and engineering chimeric tumor antigen receptors could improve their specificity and cytotoxicity. In this review, NK cells in tumor immunotherapy are discussed, and a list of therapeutic NK cell lines currently undergoing preclinical and clinical trials of several kinds of tumors are reviewed.
关键词: natural killer cell natural killer cell line tumor immunotherapy genetic modification
《化学科学与工程前沿(英文)》 2022年 第16卷 第4期 页码 536-545 doi: 10.1007/s11705-021-2067-5
关键词: BCNU glioblastoma recurrence tumor resection nanoparticles hydrogel
标题 作者 时间 类型 操作
Nanovaccines for remodeling the suppressive tumor microenvironment: New horizons in cancer immunotherapy
Kai Shi, Matthew Haynes, Leaf Huang
期刊论文
Immunosuppressive tumor microenvironment contributes to tumor progression in diffuse large B-cell lymphoma
期刊论文
-1BBL expressed by eukaryotic cells activates immune cells and suppresses the progression of murine tumor
Hui QIU, Hui ZHANG, Zuohua FENG
期刊论文
Intratumor heterogeneity, microenvironment, and mechanisms of drug resistance in glioma recurrence and
Zhaoshi Bao, Yongzhi Wang, Qiangwei Wang, Shengyu Fang, Xia Shan, Jiguang Wang, Tao Jiang
期刊论文
Distinct immune escape and microenvironment between RG-like and pri-OPC-like glioma revealed by single-cell
期刊论文
Progress in tumor vascular normalization for anticancer therapy: challenges and perspectives
null
期刊论文